Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD)
Recruitment status was Recruiting
We want to study the effect of the combination of metoprolol (a beta-blocker) with formoterol (a beta-agonist) on long function in patients with Chronic Obstructive Pulmonary Disease (COPD). There are more and more clues that a beta-blocker, when well chosen and in the right dosage, won't harm the long function in patients with COPD. Since a beta-blocker can be a valuable addition to treating patients with heart problems we would like to see if this category of medication can be available for COPD patients in the future.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Pulmonary Effects of the Combination of Metoprolol and Formoterol in COPD|
- Difference in airway reactivity after treatment with metoprolol compared to placebo.
- Effect of formoterol on airway reactivity comparing metoprolol with placebo.
- Borg-scores during provocation test
- Peak-flow measurements
- Exacerbation rate and rescue medication use
|Study Start Date:||February 2006|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00288548
|Contact: Mirjam Mensing, Drs.||+31 50 524 7817||M.Mensing@MZH.nl|
|Groningen, Netherlands, 9700 RM|
|Principal Investigator:||René Aalbers, MD, PhD||Martini Hospital Groningen|